US/UK/Canada

Share

Contacts

  • Dr Einar Pontén

    CEO


    Tvistevägen 48 C SE-907 36 Umeå, Sweden
    +46 (0)70-578 34 95
    https://lipum.se

    • Quotes

    As planned, the clinical trial application has been approved and thus a very important milestone has been reached when Lipum has manage to go from preclinical to clinal development for our drug candidate SOL-116. I´m very proud of the team and everyone who has contributed to this success with great dedication
    CEO Einar Pontén
    Lipum is focused on a novel and unique way of treating chronic inflammatory diseases that we hope will satisfy a large and global medical need. We have successfully developed the biological drug candidate SOL-116, which is a fully humanized therapeutical antibody, and we now stand ready to exploit it through clinical as well as pre-clinical studies. Therefore, it is very important that we have now been able to secure further financing from committed and knowledgeable owners
    CEO Einar Pontén
    I am looking forward to these events. We are approaching clinical trials of our biological lead candidate SOL-116 and industry meetings provide good opportunities to present our progress
    Einar Pontén CEO
    Dr Bergström has valuable and extensive experience in pharmacology and clinical trials. Her strong drive and commitment will also certainly contribute to the success of our clinical development. She will be an important cog in our team, and I am delighted to welcome Helena
    CEO Einar Pontén
    Another milestone has been reached and we are indeed pleased with the results that, as expected, confirms the safety and tolerability of our antibody SOL-116. We are now looking forward to the start of our first-in-man clinical study later this year
    CEO Einar Pontén
    Sweden is at the forefront of bioanalytical chemistry and therefore I am very pleased that we have started cooperation with Pelago in Solna. This means a strengthening of our development work and the opportunity for more valuable results from clinical studies on our lead candidate SOL-116
    CEO Einar Pontén
    We are already involved in a previous project and have a rewarding collaboration with the Cardiovascular Research Center. This new grant provides continued opportunities for the research collaboration, and it is fully in line with our plan to study additional indications for our drug candidate SOL-116
    CEO Einar Pontén
    We are, according to plan, proceeding towards a significant milestone in our development and are indeed looking forward to start clinical studies in collaboration with QPS Netherlands later this year.
    CEO Einar Pontén
    A significant milestone has been reached in the development of our drug candidate. We are pleased to have APL as our partner for the next step. It is also great that this work is in good hands locally at their site here in Umeå
    CEO Einar Pontén
    Lipum's work ahead the first clinical study is continuing as planned and, in line with our strategy, we are now strengthening our team to identify additional indications for SOL-116 in parallel with the clinical program
    CEO Einar Pontén
    We are facing the next step in Lipum's development and plan for the start of clinical trials in 2022. Then, of course, it is extremely valuable to have active owners who with industrial experience can support that development
    CEO Einar Pontén
    I am very enthusiastic for the experience that Maria brings and that she takes a leader role for Lipum's competent team. This is a great step towards a successful clinical development phase for the company
    CEO Einar Pontén
    Biological drugs are generally both tricky and expensive to develop compared to small molecules, but the chance of reaching the market is significantly better. We have now reached a milestone and taken a decisive step for the start clinical trials according to plan
    Einar Pontén CEO
    We are very pleased with the progress both with regards to the results and the adherence to time plans for this mandatory work, which is required to reach our next milestone and start clinical studies.
    Einar Pontén CEO
    Lipum has reached a stage when we are preparing for clinical trials. Important intermediate goals have been achieved during the first half of the year. Toxicology- and safety studies are progressing according to plan as well as the upscaling of the production process of our drug candidate SOL-116
    CEO Einar Pontén
    It is a strength with Lipum's high scientific level and we congratulate Professor Hernell for the recognition of his scientific contributions
    Einar Pontén CEO at Lipum
    The contribution from Horizon 2020 has been central and giving us the opportunity to develop the drug candidate SOL-116. This has a new mechanism of action and potential to be the first in a new drug class for treatment of chronic inflammatory diseases
    CEO Einar Pontén
    Pick a time period -
    Tags ( Active)

    BioStock: Lipum presents promising phase I data at ACR 2024

    Lipum will present positive data from the phase I study of its drug candidate SOL-116 at the American College of Rheumatology (ACR) Annual Meeting 2024, a leading global conference in rheumatology. The interim results confirm that SOL-116 demonstrates a favourable safety profile and pharmacokinetics in line with expectations. The study approaches its conclusion, and Lipum plans to share the final report in the first quarter of 2025.Read the full article at biostock.se : https://www.biostock.se/en/2024/11/lipum-presents-promising-phase-i-data-at-acr-2024/

    Lipum will present at the BioStock Life Science Summit, November 21

    The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CEO Ola Sandborgh will present Lipum to industry leaders, specialist investors and potential partners.The Summit connects innovation and capital, providing small-to-medium size Nordic companies from a wide range of therapeutic areas the platform and opportunity to make their case to both Swedish and international investors as well as top-level potential partners in a unique boutique setting.    Date: 21 November Time: 09:50 Location: Auditorium at Medicon Village, Lund Read more

    BioStock: Lipum and KI explore the mode of action

    Lipum is taking a new approach to treating chronic inflammatory diseases by targeting the protein BSSL. Through a collaboration with the Karolinska Institute, the company aims to gain deeper insights into BSSL’s role in inflammation and clarify the mechanism of action of their lead drug candidate, SOL-116. BioStock spoke with project leader Associate Professor Bence Réthi to learn more.Read the full article at biostock.se : https://www.biostock.se/en/2024/10/lipum-and-ki-explore-the-mode-of-action/ This is a press release from BioStock - Connecting

    BioStock: Lipum approaches the finish line in the study – last patient recruited

    Lipum has recruited all rheumatoid arthritis patients for the final stage of its phase I study with SOL-116. With a 90-day follow-up period remaining, the study is on track for completion around the end of the year. CEO Ola Sandborgh discusses this milestone in an interview.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/lipum-approaches-the-finish-line-in-the-study-last-patient-recruited/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    BioStock: Lipum and NorthX Biologics – a deep dive into the collaboration and production process

    Lipum has initiated the manufacturing process of SOL-116 for phase II studies in collaboration with the company’s partner, NorthX Biologics, a leading manufacturer of advanced biological drugs. BioStock reached out to Janet Hoogstraate at NorthX Biologics to learn more about the manufacturing process.Read the full article at biostock.se : https://www.biostock.se/en/2024/09/lipum-and-northx-biologics-a-deep-dive-into-the-collaboration-and-production-process/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    BioStock: Lipum recruits new CMO – “I have been following their research for a while and am impressed”

    In preparation for the continued clinical development of SOL-116 in rheumatoid arthritis, Lipum has strengthened its management team by appointing Peter Hovstadius as the new Chief Medical Officer. Peter brings extensive experience in clinical drug development from leading roles at companies such as XNK Therapeutics, Novartis, and MSD.– It is important for me to work in an organisation that not only has great ideas but also the capacity to turn those ideas into reality, and always with the patient in mind, says Peter in an interview.Read the full article at biostock.se 

    BioStock: Lipum's CEO summarizes the half-year – continued positive study data

    Lipum's report for the first half of 2024 highlights the positive interim results from the phase I study with SOL-116. The company has started preparations for phase II trials in rheumatoid arthritis, including initiating the collaboration with NorthX Biologics for the manufacturing of SOL-116. BioStock reached out to Lipum's CEO Ola Sandborgh to learn more about these development, as well as the audit report of the Horizon 2020 project which may result in them being liable for repayment.Read the full article at biostock.se : https://www.biostock.se/en/2024/

    BioStock: Lipum strengthens the board with commercial expertise

    Lipum has chosen to strengthen the Board of Directors with Åsa Magnusson, who has more than 30 years of experience in the pharmaceutical industry and expertise in commercialisation. BioStock reached out to Åsa to find out more about her background and what she hopes to bring to Lipum’s board.Read the full article at biostock.se : https://www.biostock.se/en/2024/07/lipum-strengthens-the-board-with-commercial-expertise/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    BioStock: Lipum’s CEO comments on multiple-dose results in phase I

    Following the positive single-dose results from the phase I study evaluating SOL-116, Lipum is now presenting additional promising data. The multiple-dose part of the study is now complete, and the safety profile continues to look good. Recruitment is currently ongoing for the third and final part, which involves rheumatoid arthritis patients.Read the full article at biostock.se : https://www.biostock.se/en/2024/06/lipums-ceo-comments-on-multiple-dose-results-in-phase-i/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

    BioStock: Flerie Invest continues to support Lipum

    Flerie Invest is Lipum’s largest shareholder and holds over half of the company’s shares. The investment company recently demonstrated continued support by participating in Lipum’s rights issue and subsequently granting a loan commitment of SEK 20 million. BioStock contacted Flerie Invest’s CEO Ted Fjällman and Senior Advisor Carl-Johan Spak to learn more.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/flerie-invest-continues-to-support-lipum/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

    BioStock: Lipum’s CEO looks ahead after the rights issue

    Lipum’s rights issue was subscribed to 42.6 per cent, of which approximately 35.7 percent was secured through subscription commitments. This means that the company will receive approximately SEK 79.7 million, which will be used to complete the phase I study with SOL-116, manufacturing and other preparations for phase II.– I would like to extend a big thank you to everyone who participated in the rights issue. Our successful development can continue according to plan, says CEO Ola Sandborgh.Read the full article at biostock.se : https://www.biostock.se/en/

    BioStock: Lipum seeks patent protecting inflammation-driven cancer treatment

    Lipum has submitted an international patent application for SOL-116 as a treatment for inflammation-driven cancer. The patent application is based on the company’s research demonstrating that SOL-116 inhibits the growth of cancer cells by blocking the target protein BSSL. Additionally, studies on breast cancer patients indicate that high expression of BSSL correlates with a poor prognosis and shorter survival.Read the full article at biostock.se : https://www.biostock.se/en/2024/04/lipum-seeks-patent-protecting-inflammation-driven-cancer-treatment/ This is

    BioStock: Lipum has included first RA patient

    Lipum recently announced that the first patient with rheumatoid arthritis has been included and dosed in ongoing phase I clinical trial with SOL-116 in the Netherlands. Previously, only healthy subjects were included in the study, but now the first patient has received a dose of SOL-116 or placebo. To find out more, we contacted Lipum’s Clinical Project Leader, Agneta Wennerholm, who is involved in the design and project management of the study.Read the full article at biostock.se : https://www.biostock.se/en/2024/03/lipum-has-included-first-ra-patient/

    BioStock: Lipum advances to phase II with capital raise, moves production to Sweden

    On leap day, Lipum published the year-end report for 2023, where CEO Ola Sandborgh describes the progress as a “flying start to an exciting journey.” On the same day, Lipum announced a rights issue of SEK 187 million to advance SOL-116 into phase II. In addition, the company has decided to relocate its contract manufacturing of SOL-116 back to Sweden through an agreement with NorthX Biologics. Ola Sandborgh elaborates on the latest news in an interview.Read the full article at biostock.se : https://www.biostock.se/en/2024/03/lipum-advances-to-phase-ii-with-

    BioStock: Lipum's CEO comments on the positive study results

    Umeå-based Lipum has successfully completed the first part of the clinical phase I study where the drug candidate SOL-116 is tested in healthy subjects. The results confirm that SOL-116 continues to have a good safety profile and desirable pharmacokinetic profile. The candidate interacts with its target protein BSSL and reduces the levels of BSSL in blood plasma. Lipum's CEO Ola Sandborgh tells us more about the results in an interview.Read the full article at biostock.se : https://www.biostock.se/en/2024/02/lipums-ceo-comments-on-the-positive-study-results/

    BioStock: CEO of Lipum looks ahead to 2024

    Throughout 2023, Lipum's primary focus has been on the clinical phase I study with SOL-116. A mid-year capital raise empowered the company to further accelerate and a CEO transition was announced in the latter part of the year. Ola Sandborgh is now assuming the helm for the company's next developmental phase, and BioStock reached out to delve into the plans for 2024.Read the full article at biostock.se : https://www.biostock.se/en/2023/12/ceo-of-lipum-looks-ahead-to-2024/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.

    BioStock: Lipum’s SOL-116 sparked interest at BIO-Europe

    On November 6-8, it was once again time for BIO-Europe, Europe’s largest partnering conference in the life science sector. Lipum’s CEO Einar Pontén and business developer Sven Undeland were there to present the latest progress in the company’s drug development to potential partners and investors. Einar Pontén shared his insights from this year’s BIO-Europe in Munich.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/lipums-sol-116-sparked-interest-at-bio-europe/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    BioStock: Ola Sandborgh takes over as CEO of Lipum

    Lipum has appointed Ola Sandborgh as their new CEO, effective from December 1, 2023. With over 30 years of experience in the pharmaceutical industry, he takes over the helm from current CEO Einar Pontén, who will remain in the company in a new role focused on business development. BioStock had the opportunity to interview both Sandborgh and Pontén about the upcoming CEO change and the company’s development plans.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/ola-sandborgh-takes-over-as-ceo-of-lipum/ This is a press release from BioStock - Connecting

    BioStock: New CMO strengthens Lipum ahead of continued clinical development

    Lipum is in the final stages of the clinical phase I study with SOL-116. In parallel, the company is preparing for the next step, a phase II study in rheumatoid arthritis. To strengthen its team for this, the company has recently recruited Karin Franck-Larsson as CMO. BioStock had the opportunity to interview Karin about her background and her expectations for her new role.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/new-cmo-strengthens-lipum-ahead-of-continued-clinical-development/ This is a press release from BioStock - Connecting Innovation & Capital.

    BioStock Investor Meeting: Lipum

    Lipum presented at BioStock Investor Meeting, September 20. The event took place in Stockholm, featuring several exciting life science companies presenting their business cases to investors and potential partners.See the presentation via: BioStock Investor Meeting September 2023 | Lipum - YouTube  See the interview via (in Swedish):  BioStock Investor Meeting | Intervju med Lipum | September 2023 - YouTube  This is a press release from BioStock - Connecting Innovation & Capital. https://www.

    BioStock: Lipum reports Q2 and increases the pace

    In the report for the second quarter, biopharmaceutical company Lipum announces that they are increasing the pace of development of SOL-116 for rheumatoid arthritis. The clinical phase I study with the candidate is progressing according to plan and the company has identified a possibility to accelerate the second part of the study. With financial resources in place, the company looks forward to reporting results from the study in early 2024.Read the full article at biostock.se: https://www.biostock.se/en/2023/09/lipum-reports-q2-and-increases-the-pace/ This is a press release from

    BioStock: Lipum publishes important results in journal

    Lipum’s drug development is based on the protein bile-salt stimulated lipase in the immune system. Recently, the journal PLOS ONE published a scientific article verifying BSSL as a promising target molecule for the treatment of chronic inflammation. BioStock contacted Lipum’s CSO Susanne Lindquist to learn more about the publication.Read the full article at biostock.se: https://www.biostock.se/en/2023/08/lipum-publishes-important-results-in-journal/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media